Amino acids 150-249 from the human protein were used as the immunogen for this recombinant CDX2 antibody.
The intestine-specific transcription factors CDX1 and CDX2 are important for directing intestinal development, differentiation, proliferation and maintenance of the intestinal phenotype. CDX2 protein expression has been seen in GI carcinomas. Anti-CDX2 has been useful to establish GI origin of metastatic adenocarcinomas and carcinoids and is especially useful to distinguish metastatic colorectal adenocarcinoma from lung adenocarcinoma. However, mucinous carcinomas of the ovary also express CDX2 protein. It limits the usefulness of this marker in the distinction of metastatic colorectal adenocarcinoma from mucinous carcinoma of the ovary.
Prediluted in 1X PBS, 0.1 mg/ml BSA (US sourced), 0.05% sodium azide, *For IHC use only*
Antibody Type:
Primary Antibody
Application Dilute:
The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Application Notes:
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the recombinant CDX2 antibody to be titered up or down for optimal performance.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* VAT and and shipping costs not included. Errors and price changes excepted
